The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial
Wu J, Pei F, Zhou L, et al. BMJ 2025;388:e082583.
What it found
28-day death rates were 23.4% with thymosin alpha-1 and 24.1% with placebo (hazard ratio 0.99, 95% CI 0.77 to 1.27). No secondary or safety outcome differed. In prespecified subgroups, patients under 60 had higher mortality on the drug (hazard ratio 1.67) and patients with diabetes lower (0.58).
Limitations
22 centres in China only. Subgroup findings may be due to chance. Partly funded by SciClone, and several authors received grants or fees from it.
Research and education only. Not medical advice. Many peptides on this site are not approved by the FDA for human use. Doses shown are the ones used in published studies and are not a recommendation. Talk to a licensed clinician before using any of them. Read the full disclaimer.